99 results on '"Im, KyungAh"'
Search Results
2. Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease
3. Abstract 14714: Long-Term Neurocognitive Safety of LDL-C Lowering With Evolocumab: Open-Label Extension Data From FOURIER
4. Abstract 14566: Long-Term Efficacy of Evolocumab in Patients With and Without Multivessel Coronary Artery Disease
5. Abstract 12103: Intraindividual Variability in Serial Lipoprotein(a) Concentration Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial
6. REDUCTION IN TOTAL CARDIOVASCULAR EVENTS WITH THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE COMBINED FOURIER AND FOURIER OPEN-LABEL EXTENSION (OLE) STUDIES
7. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE
8. Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54
9. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
10. Re‐adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study‐level meta‐analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase‐4 (DPP‐4) inhibitors
11. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial
12. Abstract 11524: Ezetimibe Consistently Reduces LDL-C with Little Interindividual Variability in 14,970 Patients Post-ACS
13. Abstract 9399: A Targeted Proteomic Approach Identifies Novel Biomarkers Associated With Risk of Myocardial Infarction in Post-Menopausal Women
14. Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
15. A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48
16. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes
17. A TARGETED PROTEOMIC APPROACH IDENTIFIES NOVEL BIOMARKERS OF ARTERIAL THROMBOEMBOLIC RISK IN ENGAGE AF-TIMI 48
18. Causes and Risk Factors for Death in Diabetes
19. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials
20. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
21. Abstract 13787: Efficacy of Lowering Low-density Lipoprotein Cholesterol in Elderly Subjects: A Systematic Review and Meta-analysis of Randomized Controlled Trials
22. Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58
23. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials
24. Cognition After Lowering LDL-Cholesterol With Evolocumab
25. SEX AND PERMANENT DRUG DISCONTINUATION IN CLINICAL TRIALS: INSIGHTS FROM THE TIMI TRIALS
26. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
27. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography
28. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
29. Outcomes of Women Compared With Men After Non–ST-Segment Elevation Acute Coronary Syndromes
30. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
31. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes
32. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease
33. Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53
34. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
35. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus
36. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
37. INTERINDIVIDUAL VARIABILITY IN WEIGHT LOSS WITH LORCASERIN: AN ANALYSIS FROM THE CAMELLIA-TIMI 61 STUDY
38. PERSISTENCE OF VALVULOPATHY IN THE CAMELLIA-TIMI 61 TRIAL OF LORCASERIN IN OBESE OR OVERWEIGHT PATIENTS AT INCREASED CARDIOVASCULAR RISK
39. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial)
40. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
41. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
42. Abstract 16679: Plasma Omega-6 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome
43. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
44. Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials
45. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels
46. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome
47. Impact of Antithrombotic Regimen on Mortality, Ischemic, and Bleeding Outcomes after Transcatheter Aortic Valve Replacement
48. Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome
49. INFLAMMATORY AND CARDIAC BIOMARKERS ARE ASSOCIATED WITH RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM SAVOR-TIMI 53
50. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.